Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX87 + pertuzumab
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HLX87 + pertuzumab is a combination therapy being developed by Shanghai Henlius Biotech for the treatment of HER2-positive breast cancer. HLX87 is an antibody-drug conjugate (ADC) consisting of a humanized anti-HER2 monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a stable, cleavable open-chain linker. Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 (HER2). The combination is designed to provide dual HER2 blockade and potent cytotoxic delivery to overcome resistance and improve efficacy in patients with recurrent or metastatic disease. It is currently being evaluated in a Phase 2/3 clinical trial (HLX87-BC001) as a first-line treatment.
- Brand names
- Perjeta
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on HLX87 + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX87 + pertuzumab.